Novo Nordisk donated a license for its very extensive small-molecule compound library to the National Center for Drug Screening (NCDS), which is affiliated with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. The compound library contains an estimated 325,000 chemical structures. Because Novo Nordisk is turning its attention from small-molecule drugs to protein-based compounds, the company wanted the library, accumulated over decades of research, to be put to good use. It feels that NCDS will be able to accomplish that by using the library to find drugs for unmet needs in underdeveloped countries.  More details...

Stock Symbol: (NYSE: NVO)